Efficacy and safety of recombinant tissue plasminogen activator and gas versus bevacizumab and gas for subretinal haemorrhage
Acta Ophthalmologica, 04/20/2012Mayer WJ et al.
Both initial treatment regimen lead to improved functional results after 1 year. However, patients, not suffering from adverse events, who underwent initial treatment with recombinant tissue plasminogen activator (rtPA) and gas showed better results. To maintain visual acuity, controlling neovascular age–related macular degeneration by anti–Vascular Endothelial Growth Factor treatment regime after initial treatment with rtPA+gas is important for all cases.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.